EGFR and breast carcinoma: The conclusion of ERBB2 inhibition of autophagy was drawn mainly based on the observation that lapatinib, an inhibitor for both EGFR and ERBB2 tyrosine kinases, increased autophagy in ERBB2-expressing breast cancer cells [17,18,28].